“We are excited to present a new study showing 88% of planned early stage total revisions changed to partial revisions when VERASENSE was used in revision TKA procedures. This reduction represents very meaningful clinical and financial benefits to both patients and providers. This is just one of many studies showing the significant clinical and economic advantages of VERASENSE that have been recently released,” said Ivan Delevic, President and Chief Executive Officer of OrthoSensor, Inc.
The distinguished presenters at the OrthoSensor Booth #5823 are as follows:
Wednesday, March 15, 2017
10:30 am – Gregory J. Golladay, MD – Virginia Commonwealth University
2:00 pm – Michael Mont, MD – Cleveland Clinic
Thursday, March 16, 2017
10:30 am – Jimmy Chow, MD – St. Luke’s Hospital
2:00 pm – Patrick Meere, MD – NYU Hospital for Joint Diseases
Friday, March 17, 2017
11:00 am – David Fabi, MD – Scripps Mercy Hospital San Diego
About OrthoSensor, Inc.
OrthoSensor, Inc., a leader in Sensor-Assisted Total Knee Arthroplasty develops and commercializes intelligent orthopedic devices and data services that provide quantitative feedback to surgeons and hospitals. The company’s intelligent orthopaedic devices utilize advanced proprietary sensor and communications technologies, coupled with the company’s innovative software products, to facilitate evidence-based decisions in orthopaedic surgery – with the goal of improving patient outcomes and potentially reducing the cost of treating musculoskeletal disease.
OrthoSensor®, VERASENSE™, and ORTHOLOGIQ™ are trademarks of OrthoSensor, Inc.
Media Contact: Yvette Cuello, (954)666-0282, email@example.com
SOURCE OrthoSensor, Inc.